CA2724774C - Pyrazolospiroketone acetyl-coa carboxylase inhibitors - Google Patents

Pyrazolospiroketone acetyl-coa carboxylase inhibitors Download PDF

Info

Publication number
CA2724774C
CA2724774C CA2724774A CA2724774A CA2724774C CA 2724774 C CA2724774 C CA 2724774C CA 2724774 A CA2724774 A CA 2724774A CA 2724774 A CA2724774 A CA 2724774A CA 2724774 C CA2724774 C CA 2724774C
Authority
CA
Canada
Prior art keywords
mmol
minutes
hplc
retention time
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2724774A
Other languages
English (en)
French (fr)
Other versions
CA2724774A1 (en
Inventor
Jeffrey Wayne Corbett
Richard Louis Elliott
Kevin Daniel Freeman-Cook
David Andrew Griffith
Dennis Paul Phillion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp SRL filed Critical Pfizer Corp SRL
Publication of CA2724774A1 publication Critical patent/CA2724774A1/en
Application granted granted Critical
Publication of CA2724774C publication Critical patent/CA2724774C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2724774A 2008-05-28 2009-05-18 Pyrazolospiroketone acetyl-coa carboxylase inhibitors Expired - Fee Related CA2724774C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US5665208P 2008-05-28 2008-05-28
US61/056,652 2008-05-28
US5868908P 2008-06-04 2008-06-04
US61/058,689 2008-06-04
US17151909P 2009-04-22 2009-04-22
US61/171,519 2009-04-22
PCT/IB2009/005649 WO2009144554A1 (en) 2008-05-28 2009-05-18 Pyrazolospiroketone acetyl-c0a carboxylase inhibitors

Publications (2)

Publication Number Publication Date
CA2724774A1 CA2724774A1 (en) 2009-12-03
CA2724774C true CA2724774C (en) 2013-06-25

Family

ID=40974611

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2724774A Expired - Fee Related CA2724774C (en) 2008-05-28 2009-05-18 Pyrazolospiroketone acetyl-coa carboxylase inhibitors

Country Status (6)

Country Link
US (1) US8318762B2 (cg-RX-API-DMAC7.html)
EP (1) EP2297163B1 (cg-RX-API-DMAC7.html)
JP (1) JP5435592B2 (cg-RX-API-DMAC7.html)
CA (1) CA2724774C (cg-RX-API-DMAC7.html)
ES (1) ES2545231T3 (cg-RX-API-DMAC7.html)
WO (1) WO2009144554A1 (cg-RX-API-DMAC7.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009144554A1 (en) 2008-05-28 2009-12-03 Pfizer, Inc. Pyrazolospiroketone acetyl-c0a carboxylase inhibitors
PT2499139E (pt) * 2009-11-10 2014-02-10 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
PL2547679T3 (pl) 2010-03-19 2016-02-29 Pfizer Pochodne 2,3-dihydro-1H-inden-1-ylo-2,7-diazaspiro[3.5]nonanu i ich zastosowanie jako antagonistów lub odwrotnych agonistów receptora greliny
EP2595989B1 (en) 2010-05-06 2016-07-13 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
SI2621493T1 (sl) 2010-09-30 2016-10-28 Pfizer Inc. Zaviralci N1-pirazolospiroketon acetil-CoA-karboksilaze
MX2013004733A (es) * 2010-10-29 2013-07-02 Pfizer Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
PL2670752T3 (pl) 2011-02-02 2016-09-30 Pirolopirazynowe spirocykliczne piperydynoamidy jako modulatory kanałów jonowych
MX2013009393A (es) * 2011-02-18 2013-08-29 Vertex Pharma Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
ES2618929T3 (es) 2011-03-14 2017-06-22 Vertex Pharmaceuticals Incorporated Morfolina-Spiro piperidina amida cíclica como moduladores del canal iónico
HRP20151397T1 (hr) * 2011-04-22 2016-01-15 Pfizer Inc. DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE
JP2014520879A (ja) 2011-07-15 2014-08-25 ファイザー・インク Gpr119調節因子
WO2013014569A1 (en) 2011-07-22 2013-01-31 Pfizer Inc. Quinolinyl glucagon receptor modulators
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
SG11201401531RA (en) 2011-11-11 2014-07-30 Pfizer 2-thiopyrimidinones
PE20142164A1 (es) 2012-04-06 2014-12-27 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6110937B2 (ja) 2012-05-04 2017-04-05 ファイザー・インク APP、BACE1、およびBACE2の阻害剤としての複素環式置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
JP2015529239A (ja) 2012-09-20 2015-10-05 ファイザー・インク アルキル置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
CN102898374B (zh) * 2012-11-05 2016-03-23 上海毕得医药科技有限公司 一种1h-吲唑类衍生物的制备方法
JP2016502978A (ja) 2012-12-11 2016-02-01 ファイザー・インク BACE1の阻害剤としてのヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
WO2014097038A1 (en) 2012-12-19 2014-06-26 Pfizer Inc. CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
EP2956458B1 (en) 2013-02-13 2017-08-09 Pfizer Inc Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
AU2014319990A1 (en) 2013-09-12 2016-02-25 Pfizer Inc. Use of acetyl-CoA carboxylase inhibitors for treating acne vulgaris
EP3055300B1 (en) 2013-10-09 2018-03-07 Pfizer Inc Antagonists of prostaglandin ep3 receptor
EP3072884B1 (en) 2013-11-20 2020-01-01 Sanwa Kagaku Kenkyusho Co., Ltd. 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purposes
CN103910682B (zh) * 2013-11-28 2016-03-02 大连理工大学 一种基于邻苯二胺环化的苯并咪唑类化合物制备方法
EA032356B1 (ru) 2014-03-17 2019-05-31 Пфайзер Инк. Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств
WO2015150995A1 (en) 2014-04-04 2015-10-08 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
KR20180078347A (ko) 2014-04-10 2018-07-09 화이자 인코포레이티드 2-아미노-6-메틸-4,4a,5,6-테트라히드로피라노[3,4-d][1,3]티아진-8a(8H)-일-1,3-티아졸-4-일 아미드
WO2016092413A1 (en) 2014-12-10 2016-06-16 Pfizer Inc. Indole and indazole compounds that activate ampk
EP3237401B1 (en) 2014-12-22 2019-03-06 Pfizer Inc Antagonists of prostaglandin ep3 receptor
JP2018515480A (ja) 2015-05-05 2018-06-14 ファイザー・インク 2−チオピリミジノン
JP2018516254A (ja) 2015-05-29 2018-06-21 ファイザー・インク バニン1酵素の阻害薬としての新規なヘテロ環化合物
US11472805B2 (en) 2015-06-17 2022-10-18 Pfizer, Inc. Tricyclic compounds and their use as phosphodiesterase inhibitors
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
JP2018527337A (ja) 2015-08-13 2018-09-20 ファイザー・インク 二環式縮合ヘテロアリールまたはアリール化合物
HUE053705T2 (hu) 2015-08-27 2021-07-28 Pfizer Biciklusos kondenzált heteroaril- vagy aril- vegyületek IRAK4 modulátorokként
WO2017037567A1 (en) 2015-09-03 2017-03-09 Pfizer Inc. Regulators of frataxin
EP3353183A1 (en) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3]thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl]amides
WO2017051303A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
WO2017051294A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
UA121271C2 (uk) 2015-12-29 2020-04-27 Пфайзер Інк. Заміщені 3-азабіцикло[3.1.0]гексани як інгібітори кетогексокінази
EP3484876A1 (en) 2016-07-14 2019-05-22 Pfizer Inc Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
WO2018151126A1 (ja) 2017-02-14 2018-08-23 富士フイルム株式会社 インダゾール化合物の製造方法およびインダゾール化合物
WO2019133445A1 (en) 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles as inhibitors of vanin-1
MA53496A (fr) 2018-08-31 2021-12-08 Pfizer Combinaisons pour le traitement de la stéatohépatite non alcoolique (nash)/maladie du foie gras non alcoolique (nafld) et de maladies associées
WO2020102575A1 (en) 2018-11-16 2020-05-22 Inception Ibd, Inc. Heterocyclic aminothiazoles and uses thereof
EP3972596B1 (en) 2019-05-20 2025-07-16 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
CN110734401A (zh) * 2019-10-10 2020-01-31 长沙麓兴生物科技有限公司 一种氮未取代-4-甲酰基吡唑的制备方法
HRP20241159T1 (hr) 2020-02-07 2024-12-06 Gasherbrum Bio, Inc. Heterociklički agonisti za glp-1
CN111574530B (zh) * 2020-04-21 2022-07-26 徐州医科大学 一种acc抑制剂及其医药用途
US20230331699A1 (en) * 2020-06-22 2023-10-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Preparation method for cdk4/6 inhibitor
CN112625030A (zh) * 2020-12-25 2021-04-09 杭州澳赛诺生物科技有限公司 一种一锅法合成n-保护3-溴代吡唑的合成方法
CN119137124A (zh) 2022-03-09 2024-12-13 加舒布鲁姆生物公司 杂环glp-1激动剂
JP2025513071A (ja) 2022-04-14 2025-04-22 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式glp-1アゴニスト
AU2023316863A1 (en) 2022-07-29 2025-02-13 Pfizer Inc. Novel acc inhibitors
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
AU2023396387A1 (en) 2022-12-15 2025-06-26 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
JP2025541334A (ja) 2022-12-16 2025-12-18 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト ベンズイミダゾール誘導体
WO2025036472A1 (en) * 2023-08-16 2025-02-20 Pharmaengine, Inc. Spirocyclic mta-cooperative prmts inhibitor
WO2025133948A1 (en) 2023-12-21 2025-06-26 Pfizer Inc. Acetyl coa-carboxylase (acc) inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200400980A1 (ru) 2002-02-27 2005-02-24 Пфайзер Продактс Инк. Ингибиторы асс
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004092179A1 (ja) 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
US20050267221A1 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
BRPI0613427A2 (pt) * 2005-07-19 2012-10-30 Merck & Co Inc composto ou seu sal ou éster, composição farmacêutica, agente terapêutico, e , uso do composto ou seu sal ou éster
CA2617042A1 (en) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
DE102006016566B4 (de) * 2005-09-22 2008-06-12 Beru Ag Zusammengesetzter Leiter, insbesondere für Glühkerzen für Dieselmotoren
ATE493412T1 (de) 2005-11-18 2011-01-15 Merck Sharp & Dohme Spirohydantoin-aryl-cgrp-rezeptorantagonisten
JP2009526868A (ja) 2006-02-15 2009-07-23 アボット・ラボラトリーズ 新規なアセチル−CoAカルボキシラーゼ(ACC)阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
ATE552262T1 (de) 2006-11-29 2012-04-15 Pfizer Prod Inc Spiroketone als inhibitoren von acetyl-coa- carboxylase
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
US20100113418A1 (en) 2007-02-20 2010-05-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP2195321B1 (en) 2007-04-12 2016-10-19 Pfizer Inc. 3-amido-pyrrolo[3,4-c]pyrazole-5(1h, 4h,6h) carbaldehyde derivatives as inhibitors of protein kinase c
US7981904B2 (en) * 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
US20110009443A1 (en) 2008-05-28 2011-01-13 Kevin Daniel Freeman-Cook Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
WO2009144554A1 (en) 2008-05-28 2009-12-03 Pfizer, Inc. Pyrazolospiroketone acetyl-c0a carboxylase inhibitors
JP5501256B2 (ja) 2008-07-04 2014-05-21 Msd株式会社 新規スピロクロマノンカルボン酸
JP2011528034A (ja) * 2008-07-14 2011-11-10 クロップソリューション,インコーポレイテッド アセチル−補酵素カルボキシラーゼの修飾因子およびその使用方法
PT2499139E (pt) 2009-11-10 2014-02-10 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
WO2011058473A1 (en) 2009-11-10 2011-05-19 Pfizer Inc. N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors
SI2621493T1 (sl) 2010-09-30 2016-10-28 Pfizer Inc. Zaviralci N1-pirazolospiroketon acetil-CoA-karboksilaze

Also Published As

Publication number Publication date
ES2545231T3 (es) 2015-09-09
US20110028390A1 (en) 2011-02-03
US8318762B2 (en) 2012-11-27
WO2009144554A1 (en) 2009-12-03
JP5435592B2 (ja) 2014-03-05
CA2724774A1 (en) 2009-12-03
EP2297163A1 (en) 2011-03-23
JP2011521939A (ja) 2011-07-28
EP2297163B1 (en) 2015-07-08

Similar Documents

Publication Publication Date Title
CA2724774C (en) Pyrazolospiroketone acetyl-coa carboxylase inhibitors
US11673890B2 (en) N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
EP2097420B1 (en) Spiroketone inhibitors of acetyl-coa carboxylase
AU2010317501B2 (en) N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
AU2011322117B2 (en) N1/N2-lactam acetyl-CoA carboxylase inhibitors
US20110009443A1 (en) Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
SG194142A1 (en) Pyrazolospiroketone derivatives for use as acetyl - coa carboxylase inhibitors
US20120225900A1 (en) N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2022179940A1 (en) Furoindazole derivatives as gpr84 antagonists

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220518